HCSGD entry for RRM2
1. General information
| Official gene symbol | RRM2 |
|---|---|
| Entrez ID | 6241 |
| Gene full name | ribonucleotide reductase M2 |
| Other gene symbols | R2 RR2 RR2M |
| Links to Entrez Gene | Links to Entrez Gene |
2. Neighbors in the network
This gene isn't in Literature mining network.
3. Gene ontology annotation
GO ID | GO term | Evidence | Category |
|---|---|---|---|
| GO:0000082 | G1/S transition of mitotic cell cycle | TAS | biological_process |
| GO:0000083 | Regulation of transcription involved in G1/S transition of mitotic cell cycle | TAS | biological_process |
| GO:0000278 | Mitotic cell cycle | TAS | biological_process |
| GO:0004748 | Ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor | ISS NAS | molecular_function |
| GO:0005515 | Protein binding | IPI | molecular_function |
| GO:0005654 | Nucleoplasm | TAS | cellular_component |
| GO:0005829 | Cytosol | TAS | cellular_component |
| GO:0006260 | DNA replication | IEA | biological_process |
| GO:0009186 | Deoxyribonucleoside diphosphate metabolic process | IEA | biological_process |
| GO:0009263 | Deoxyribonucleotide biosynthetic process | ISS | biological_process |
| GO:0015949 | Nucleobase-containing small molecule interconversion | TAS | biological_process |
| GO:0016491 | Oxidoreductase activity | IEA | molecular_function |
| GO:0044281 | Small molecule metabolic process | TAS | biological_process |
| GO:0046872 | Metal ion binding | IEA | molecular_function |
| GO:0051290 | Protein heterotetramerization | IEA | biological_process |
| GO:0055086 | Nucleobase-containing small molecule metabolic process | TAS | biological_process |
Entries Per Page
Displaying Page of
4. Expression levels in datasets
- Meta-analysis result
| p-value up | p-value down | FDR up | FDR down |
|---|---|---|---|
| 0.9984804719 | 0.0000059800 | 0.9999902473 | 0.0069833333 |
- Individual experiment result
( "-" represent NA in the specific microarray platform )
( "-" represent NA in the specific microarray platform )
| Data source | Up or down | Log fold change |
|---|---|---|
| GSE11954 | Down | -3.1713049843 |
| GSE13712_SHEAR | Down | -0.1358117971 |
| GSE13712_STATIC | Up | 0.2692828617 |
| GSE19018 | Down | -0.7101966063 |
| GSE19899_A1 | Down | -3.6943823496 |
| GSE19899_A2 | Down | -3.2821405855 |
| PubMed_21979375_A1 | Down | -2.6666287355 |
| PubMed_21979375_A2 | Down | -5.3744068451 |
| GSE35957 | Down | -6.4484495518 |
| GSE36640 | Down | -3.0814900271 |
| GSE54402 | Down | -0.6053871975 |
| GSE9593 | Down | -2.3147359032 |
| GSE43922 | Down | -2.3805081440 |
| GSE24585 | Down | -0.2466774670 |
| GSE37065 | Down | -1.0351089326 |
| GSE28863_A1 | - | - |
| GSE28863_A2 | - | - |
| GSE28863_A3 | - | - |
| GSE28863_A4 | - | - |
| GSE48662 | Down | -2.2191085206 |
5. Regulation relationships with compounds/drugs/microRNAs
- Compounds
Not regulated by compounds
- Drugs
Name | Drug | Accession number |
|---|---|---|
| Imexon | DB05003 | - |
| Gallium nitrate | DB05260 | - |
| motexafin gadolinium | DB05428 | - |
| GTI 2040 | DB05801 | - |
- MicroRNAs
- mirTarBase
MiRNA_name | mirBase ID | miRTarBase ID | Experiment | Support type | References (Pubmed ID) |
|---|---|---|---|---|---|
| hsa-let-7b-5p | MIMAT0000063 | MIRT005050 | Microarray | Functional MTI (Weak) | 17699775 |
| hsa-let-7b-5p | MIMAT0000063 | MIRT005050 | Proteomics | Functional MTI (Weak) | 18668040 |
| hsa-miR-193b-3p | MIMAT0002819 | MIRT016281 | Microarray | Functional MTI (Weak) | 20304954 |
| hsa-miR-193b-3p | MIMAT0002819 | MIRT016281 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-155-5p | MIMAT0000646 | MIRT020622 | Proteomics | Functional MTI (Weak) | 18668040 |
| hsa-miR-34a-5p | MIMAT0000255 | MIRT025270 | Proteomics | Functional MTI (Weak) | 21566225 |
| hsa-miR-30a-5p | MIMAT0000087 | MIRT028473 | Proteomics | Functional MTI (Weak) | 18668040 |
| hsa-miR-24-3p | MIMAT0000080 | MIRT030469 | qRT-PCR;Microarray | Functional MTI (Weak) | 19748357 |
| hsa-miR-425-5p | MIMAT0003393 | MIRT039342 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-484 | MIMAT0002174 | MIRT041980 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-342-3p | MIMAT0000753 | MIRT043700 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-186-5p | MIMAT0000456 | MIRT045271 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-let-7g-5p | MIMAT0000414 | MIRT046565 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-30c-5p | MIMAT0000244 | MIRT047887 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-100-5p | MIMAT0000098 | MIRT048497 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-miR-26a-5p | MIMAT0000082 | MIRT050154 | CLASH | Functional MTI (Weak) | 23622248 |
| hsa-let-7a-5p | MIMAT0000062 | MIRT052385 | CLASH | Functional MTI (Weak) | 23622248 |
Entries Per Page
Displaying Page of
- mirRecord
No target information from mirRecord
6. Text-mining results about the gene
Gene occurances in abstracts of cellular senescence-associated articles: 1 abstracts the gene occurs.
PubMed ID of the article | Sentenece the gene occurs |
|---|---|
| 24200970 | Ribonucleotide reductase M2 (RRM2) plays a key role in regulating the senescence-associated cell growth arrest by controlling biogenesis of 2'-deoxyribonucleoside 5'-triphosphates (dNTPs) |
| 24200970 | The role of RRM2 in EOC remains poorly understood |
| 24200970 | Here we show that RRM2 is expressed at higher levels in EOCs compared with either normal ovarian surface epithelium (P<0 |
| 24200970 | RRM2 expression significantly correlates with the expression of Ki67, a marker of cell proliferation (P<0 |
| 24200970 | Moreover, RRM2 expression positively correlates with tumor grade and stage, and high RRM2 expression independently predicts a shorter overall survival in EOC patients (P<0 |
| 24200970 | To delineate the functional role of RRM2 in EOC, we knocked down RRM2 expression in a panel of EOC cell lines |
| 24200970 | Knockdown of RRM2 expression inhibits the growth of human EOC cells |
| 24200970 | Mechanistically, RRM2 knockdown triggers cellular senescence in these cells |
| 24200970 | These data suggest that targeting RRM2 in EOCs by suppressing its activity is a novel pro-senescence therapeutic strategy that has the potential to improve survival of EOC patients |
Entries Per Page
Displaying Page of

